Loading...
•
Dec 31, 2023
Harrow Q4 2023 Earnings Report
Harrow experienced growth and launched key products, setting the stage for future expansion.
Key Takeaways
Harrow announced its fourth quarter and year-end 2023 financial results, highlighting the company's transformation and growth in the ophthalmic pharmaceuticals market. The company launched products and began generating cash from IHEEZO, VEVYE, and TRIESENCE.
Harrow transformed from a company focused on compounded business to a leader in ophthalmic pharmaceuticals.
The company launched products and began generating cash from its Big Three products: IHEEZO, VEVYE, and TRIESENCE.
Harrow attracted experienced talent, setting the stage for growth in 2024.
The company expects significant growth from IHEEZO and continued success with VEVYE.
Forward Guidance
Harrow anticipates continued growth and success, driven by its product portfolio and strategic initiatives.
Positive Outlook
- Significant growth expected from IHEEZO.
- Continued success with VEVYE launch.
- Potential return of TRIESENCE to inventory this year.
- Company has the products, resources, and people to take advantage of opportunities.
- 2024 is shaping up to be another exciting year of growth.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...